Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Dose-dense Temozolomide in Recurrent Glioblastoma
NCT04547855Phase 2Unknown
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in glioblastoma (GBM). Status: unknown.
02
Drugs
anlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04547855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547855.